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Over the last years, immunotherapy has been 
on the rise as an effective treatment option 
in cancer. For example, immunotherapy 
targeting PD(L)-1 was found to be effective 
in non-small-cell lung cancer (NSCLC) [1], 
with response rates of approxi mately 20% 
in an unselected population and 45% in a 
selected population of patients with high 
PD-L1 expressing tumors [2]. Therefore, 
anti-PD-(L)1 has become a standard care 
for treating NSCLC in second line and in 
patients with PD-L1 expression ≥50% in 
first-line therapy.
In malignant pleural mesothelioma, 
treatment with cisplat inum/pem-
etrexed resulted in a survival benefit of 
3 months [3]. Recently, the addition of bev-
acizumab resulted in an additional survival 
benefit of nearly 3 months [4]. Currently, 
no other therapy has shown activity in 
a randomized controlled Phase III trial. 
Therefore, new treatment options are 
more than desirable. Similar to NSCLC, 
immunotherapy might have the potency 
to provide a tumor response with durable 
survival in mesothelioma [1]. Although, to 
date no randomized Phase III study using 
immunotherapy has proven effective in 
mesothelioma, the research continues 
extensively. This Editorial aims to answer 
the question if immunotherapy could be a 
viable option in mesothelioma by analyz-
ing the immune response needed for an 
effective immune-mediated tumor killing.
opportunities to make 
immunotherapy viable in 
mesothelioma
Anticancer immunity is a process con-
sisting of consecutive steps [5]. First, 
tumor-associated antigens are released by 
the tumor while it develops. Immature 
dendritic cells (DCs) can take up these 
tumor-associated antigens. Afterward, 
DCs mature, followed by migration to the 
lymphatic system. There, they can present 
the captured antigens in presence of major 
histocompatibility complex-I molecules on 
the cell membrane to T cells. In turn, these 
CD8 T cells need to travel to the tumor 
site, recognize the tumor and invade the 
tumor and initiate tumor killing.
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●● antigen recognitions & dendritic cell 
maturation
Mesothelioma is a tumor with evident less muta-
tional load than NSCLC, therefore, less tumor 
antigens are expected, resulting in a lower chance 
of tumor recognition by DCs [6]. In addition, the 
tumor microenvironment in mesothelioma has 
shown to be immune-suppressive with the pres-
ence of, for example, M2 macrophages and regu-
latory T cells (Tregs), as well as the presence of 
IL-10, M-CSF, VEGF, prostaglandins and TGF-β. 
This also impedes DCs from their potency to act 
as antigen-presenting cell to T cells [7]. In addition, 
tumors can inactivate damage-associated molecular 
pattern, which is needed for DC maturation.
For immunotherapy to be effective, tumor 
recognition is mandatory. Ex vivo generated 
activated DCs that have been ‘trained’ to pre-
sent tumor antigen could provide a possibility to 
overcome the problems stated above [8,9].
In 2010, the first clinical trial was conducted 
with ten mesothelioma patients using auto-
logous tumor lysate-pulsed DCs. After comple-
tion of chemotherapy, these mature DCs were 
injected intradermally and intravenously. Nine 
patients showed a significant increase in periph-
eral blood mononuclear cells. Four patients 
showed an increased cytotoxic activity against 
autologous tumor cells. This vaccination with 
DCs was well tolerated [8].
A follow-up trial using cyclophosphamide in 
addition to DCs resulted in a significant immuno-
activity against the tumor [9]. The mechanism of 
cyclophosphamide will be explained further below. 
To circumvent the need for autologous tumor 
material, in the follow-up trial, an allogeneic 
tumor lysate was used, which resulted in similar 
antitumor response [10]. Currently, a randomized 
Phase III study named DENIM with a planned 
enrollment of 230 patients is about to start.
Another option that is currently tested to acti-
vate DCs is vaccination with Listeria [11]. Uptake 
of the Listeria-based vaccine results in activation of 
both adapted and innate effector cells, by directly 
targeting and activating DCs in vivo. Engineered 
Listeria-based vaccine can express human meso-
thelin antigen, which is highly expressed in meso-
thelioma. Uptake of this engineered Listeria by 
DCs triggers a mesothelin targeted T-cell response.
●● antigen presentation to t cell
The next step in anticancer immunity is the 
antigen presenting of DCs to the T cells. In the 
case that DC maturation is progressing well, 
optimal T-cell activation may be insufficient 
due to lower levels of costimulatory ligands 
and MHC molecules [12]. Activation of T-cell 
receptor in absence of appropriate costimula-
tion leads to dysfunctional T cells. By using 
stimulatory antibodies (such as anti-OX40) [5], 
anticancer immunity could be increased.
The protein CTLA-4 (cytotoxic T lympho-
cyte antigen-4) is mainly found on T cells and 
has an immune inhibitory effect. T-cell activa-
tion decreases when CTLA-4 is bound to CD-80 
and CD-86. Blocking CTLA-4 could therefore 
be an effective antitumor treatment [13].
CTLA-4 blocking IgG2 antibody tremeli-
mumab has been investigated in mesothelioma in 
the DETERMINE trial: a Phase IIB placebo-con-
trolled study of tremelimumab in 571 advanced 
mesothelioma patients as second- and third-line 
treatment. In terms of patient number, it was the 
largest immunotherapy study in mesothelioma to 
date. Unfortunately, no survival benefit was seen 
in patients using tremelimumab, which might be 
explained by the treatment in second- and third-
line setting. Of note, the authors of this Editorial 
have seen a response in a patient participating in 
this trial, showing the need for more insight into 
the immune response present in a patient. One 
treatment probably will not fit all patients [14].
Another option to overcome tumor recognition 
by DCs and also T-cell presentation is to produce 
ex vivo generated T cells. Chimeric antigen recep-
tors (CARs) T-cell therapy is a form of immuno-
therapy whereby genetic engineered receptors 
expressed on T cells bind to a specific tumor-
associated antigen and activate T-cell cytotoxicity. 
These antigen-specific CARs bound T cells are 
reinfused to the patient in an effort to eradicate 
tumors. A murine model showed that administra-
tion of CAR T cells intrapleurally needs a 30-fold 
lower dose to eradicate pleural tumors than intra-
venously administered CAR T cells, which could 
be an interesting strategy in mesothelioma patients. 
The main disadvantage is that CAR T cells only 
target a specific tumor antigen, allowing for tumor 
escape mechanism avoiding that single antigen [15]. 
Another hurdle encountered in the use of CAR 
T cells in solid tumors is the difficulty in migrat-
ing to and adequately penetrating the tumor to 
unleash their cytotoxic function [16].
●● t-cell trafficking & infiltration
The next step in anticancer immunity is infil-
tration of activated T cells into the tumor. 
T-cell adhesion molecules are needed for T-cell 
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extravasation. These adhesion molecules are 
downregulated by, for example, VEGF, which 
is produced in the tumor microenvironment. 
By targeting VEGF by, for example bevaci-
zumab, several tumor mechanisms are targeted, 
among which is ineffective T-cell trafficking. 
The positive result using bevacizumab in the 
MAPS study might be partially due to more 
effective T-cell trafficking [4].
●● tumor cell killing
If the previous stages in the immunity cycle 
were passed effectively in a patient, it should 
result in an influx of CD8+ cells in the tumor. 
This is also called the ‘inflamed tumor micro-
environment’. However, recognition of MHC 
complexes on tumor cells by CD8+ T cells is 
needed for tumor cell killing. T cells are releas-
ing IFN-γ, which results in releasing of addi-
tional cancer antigens but also in expression of 
multiple coinhibitory receptors such as PD-1, 
LAG-3, TIM-3 and TIGIT, which together 
with chronic T-cell receptor signaling induces 
T-cell dysfunction [17]. An effective tumor 
treatment could be induced by blocking this 
negative feedback signal. Several trials have 
investigated PD-1/PD-L1 inhibitors in meso-
thelioma. The Keynote 28 is a Phase IB trial 
in which mesothelioma patients with a PD-L1 
≥1% were treated with pembrolizumab. This 
trial showed a disease control rate of 72% and 
an objective response rate of 20%. The median 
overall survival was 18 months [18].
The Phase II NivoMes study (nivolumab) and 
the Phase IB JAVELIN trial (avelumab) showed a 
disease control rate of approximately 50% by treat-
ing mesothelioma without a PD-L1 expression 
selection criterion. The overall response rate was 
28% in NivoMes study and 9.4% in JAVELIN 
trial [19,20].
Local immune suppression due to immune cells 
in the tumor microenvironment also impedes effec-
tive tumor killing. Although M1 macrophages 
protect the host by producing IL-12 which stim-
ulates the activation of NK and Th1 cells, M2 
macrophages downregulate these functions and 
produce IL-10, which stimulates Tregs and Th2 
cells and so suppresses CD8+ T-cell response [21,22].
Inhibition of M2 macrophages in mice resulted 
in reduced monocytes and neoangio genesis, but 
without improving survival. However, combi-
nation with DC therapy resulted in improved 
survival and enhanced CD8+ T cells, which 
induces durable antitumor immunity [23].
In addition, Tregs can promote tumor pro-
gression by inhibiting CD8+ T-cell response [22]. 
Low-dose cyclophosphamide can reduce the 
number of Tregs. This mechanism was demon-
strated in combination with DC immuno-
therapy. This trial was not powered for efficacy 
of cyclophosphamide alone, however [8].
Conclusion
As stated above, mesothelioma tumors have several 
features that can result in inferior outcomes in tri-
als using the current checkpoint inhibitors that 
have resulted in positive trials in NSCLC. Most 
mesothelioma tumors are indeed noninflamed, 
with low T-cell infiltration. In those patients, treat-
ment must focus on initiating this T-cell response. 
If the tumor is already inflamed or this has been 
archived by using a form of immunotherapy and 
no response is seen then treatment must focus on 
checkpoint inhibition or the tumor microenviron-
ment. Treatment must be tuned to the missing 
step(s) in the cancer immunity cycle, and therefore 
combination treatment can be of added value. By 
using these tools, immunotherapy may prove to be 
a viable option for mesothelioma patients.
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